ConductScience.org, home

Paper30838514

Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke.

Yang M and 3 others. Drugs, 2019. Cited by 119 papers, by iCite.

Cite this record

ConductScience Library. Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke. Papers, record 30838514. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30838514

Download JSON
Disease
ischemic stroke213 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke.
PubMed
Journal
Drugs
PubMed
Year
2019
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
119
iCite
Relative citation ratio, by iCite
6.09
iCite
Revised in PubMed
2020-02-25
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang MMinghttps://orcid.org/0000-0001-7788-3356
2Huo XXiaochuan
3Miao ZZhongrong
4Wang YYongjun

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Brain IschemiaMajor topic
Platelet Aggregation InhibitorsMajor topic
Platelet Glycoprotein GPIIb-IIIa ComplexMajor topic
StrokeMajor topic
TirofibanMajor topic
Humans
Platelet Aggregation
Stroke Rehabilitation
Thrombosis

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT07290751Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic StrokeBackgroundClinicalTrials.gov
NCT07335107Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery OcclusionResultsClinicalTrials.gov

Download CSV of trials

References114

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110436319Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment.Cerebrovasc Dis1999https://conductscience.org/library/papers/10436319PubMed
210745462Therapeutic dissolution of an intracoronary thrombus by prolonged intravenous platelet glycoprotein IIb/IIIa antagonism.J Invasive Cardiol1999https://conductscience.org/library/papers/10745462PubMed
310834640Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I--Pathophysiological and pharmacological features.Neurosurgery2000https://conductscience.org/library/papers/10834640PubMed
410835463Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia.Stroke2000https://conductscience.org/library/papers/10835463PubMed
510880411Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.Circulation2000https://conductscience.org/library/papers/10880411PubMed
611487034Anti-GPIIb/IIIa drugs: current strategies and future directions.Thromb Haemost2001https://conductscience.org/library/papers/11487034PubMed
711577835Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.Ital Heart J2001https://conductscience.org/library/papers/11577835PubMed
811719681Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases.Radiology2001https://conductscience.org/library/papers/11719681PubMed
911721100Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study.Cerebrovasc Dis2001https://conductscience.org/library/papers/11721100PubMed
1011823719Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.J Cereb Blood Flow Metab2002https://conductscience.org/library/papers/11823719PubMed
1111901016Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases.AJNR Am J Neuroradiol2002https://conductscience.org/library/papers/11901016PubMed
1211919304Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.N Engl J Med2002https://conductscience.org/library/papers/11919304PubMed
1311964126Glycoprotein IIb/IIIa antagonists--from bench to practice.Cell Mol Life Sci2002https://conductscience.org/library/papers/11964126PubMed
1412052983Lacunar stroke is the major cause of progressive motor deficits.Stroke2002https://conductscience.org/library/papers/12052983PubMed
1512083481An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.Thromb Haemost2002https://conductscience.org/library/papers/12083481PubMed
1612297567Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator.Neurology2002https://conductscience.org/library/papers/12297567PubMed
1712742983Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist.Circulation2003https://conductscience.org/library/papers/12742983PubMed
1812771267Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study.Neurology2003https://conductscience.org/library/papers/12771267PubMed
1912829861Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations.Stroke2003https://conductscience.org/library/papers/12829861PubMed
2014718754Progressing stroke: towards an internationally agreed definition.Cerebrovasc Dis2004https://conductscience.org/library/papers/14718754PubMed

See all 114 referencesDownload CSV of references

Cited by76

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 119 citations.

PMIDTitleJournalYearIn PapersSource
42839966
Association of a platelet function testing-guided intensified antiplatelet strategy with thromboembolic events after EP2 stent-assisted coil embolization in patients with unruptured intracranial aneurysms.
Front Neurol2026https://conductscience.org/library/papers/42839966PubMed
42780889Association between tirofiban administration and sex in outcomes following endovascular treatment for large vessel occlusion stroke.Front Neurol2026https://conductscience.org/library/papers/42780889PubMed
42666858Early antiplatelet therapy was associated with reduced neurological deterioration in stroke patients treated with intravenous thrombolysis.Brain Circ2026https://conductscience.org/library/papers/42666858PubMed
42646373Acute and Chronic Cerebral Hypoperfusion After Flow-Diverter Placement: Is There a Role for Extra-Intracranial Bypass? A Case Series and Narrative Literature Review.Neurol Int2026https://conductscience.org/library/papers/42646373PubMed
42432445Tirofiban Versus Alteplase for Patients With Minor Acute Ischemic Stroke: A Target Trial Emulation Study.J Am Heart Assoc2026https://conductscience.org/library/papers/42432445PubMed
42393539Association of low-dose intra-arterial plus intravenous tirofiban with improved functional outcome in branch atheromatous disease-related stroke patients with early neurological deterioration.BMC Neurol2026https://conductscience.org/library/papers/42393539PubMed
42315720Efficacy and safety of adjuvant tirofiban versus intravenous thrombolysis alone in acute ischemic stroke: an updated meta-analysis of randomized controlled trials.J Thromb Thrombolysis2026https://conductscience.org/library/papers/42315720PubMed
42315198
Efficacy and safety of early tirofiban administration after intravenous thrombolysis in patients with acute ischaemic stroke: the multicentre, randomised, double-blind, placebo-controlled RESCUE BT3 trial protocol.
Eur Stroke J2026https://conductscience.org/library/papers/42315198PubMed
42154376Uniform shear-induced platelet aggregation analysis via microfluidics fabricated from 3D-printed mold: a rapid platform for antiplatelet drug assessment.Anal Sci2026https://conductscience.org/library/papers/42154376PubMed
41995942Efficacy and safety of early intravenous administration of tirofiban after thrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.J Thromb Thrombolysis2026https://conductscience.org/library/papers/41995942PubMed
41993645Tirofiban combined with aspirin for branch atheromatous disease: a propensity score-matched study.Front Neurol2026https://conductscience.org/library/papers/41993645PubMed
41882560Efficacy and Safety of tirofiban in acute ischemic stroke patients with early neurological deterioration: a meta-analysis.BMC Neurol2026https://conductscience.org/library/papers/41882560PubMed
41822823Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Vessel.Cardiol Res2026https://conductscience.org/library/papers/41822823PubMed
41559328Impact of Prestroke Antiplatelet Therapy on the Efficacy of Intravenous Tirofiban at Preventing Early Neurological Deterioration: A Prespecified Subgroup Analysis of the TREND Trial.Am J Cardiovasc Drugs2026https://conductscience.org/library/papers/41559328PubMed
41553624Thrombolysis with Adjunctive Tirofiban in Acute Non-cardioembolic Posterior Circulation Ischemic Stroke: A Propensity Score-Matched Analysis.Neurol Ther2026https://conductscience.org/library/papers/41553624PubMed
41466170Adjunct tirofiban after intravenous thrombolysis in acute ischemic stroke: a GRADE-guided meta-analysis of randomized trials with trial sequential analysis.J Thromb Thrombolysis2026https://conductscience.org/library/papers/41466170PubMed
41458952Real-world safety of tirofiban: a disproportionality analysis using data from FAERS and WHO-VigiAccess.Front Pharmacol2025https://conductscience.org/library/papers/41458952PubMed
41456941
Tirofiban for Preventing Early Neurological Deterioration in Acute Ischemic Stroke Within 48 Hours of Onset: Evidence From a Dual-Method Analysis Using Propensity Score Matching and Multivariable Regression.
CNS Neurosci Ther2025https://conductscience.org/library/papers/41456941PubMed
41427506
Efficacy and safety of adjunctive tirofiban administration in anterior large vessel occlusion due to large artery atherosclerosis: an individual patient data pooled analysis of two randomized clinical trials.
Int J Surg2026https://conductscience.org/library/papers/41427506PubMed
41326478High glucose enhances inflammation-driven platelet adhesion to endothelial cells in vitro.Sci Rep2025https://conductscience.org/library/papers/41326478PubMed

See all 76 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FGB2244PubTator's text mininghttps://conductscience.org/library/genes/2244

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
TIROFIBANCHEMBL916Results1https://conductscience.org/library/drugs/CHEMBL916

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30838514

GET https://conductscience.org/api/papers/v1/30838514/references?page=2